Attention Deficit Disorder With Hyperactivity
Conditions
Brief summary
This randomized, double-blind, flexible-dose, placebo-controlled, parallel group study is designed to evaluate Aptensio XR® compared to placebo in preschool age children with ADHD. Male and female children ages 4 years, 0 months to 5 years, 8 months with a diagnosis of ADHD (combined, inattentive or hyperactive/impulsive) will be enrolled. There will be 6 phases in this study: a screening phase of up to 4 weeks, which will include washout if applicable, an enrollment & parent training phase lasting 2-4 weeks, an eligibility phase of up to 2 weeks to determine eligibility for the open-label phase, a 6-week open-label dose titration phase, a 2 week double-blind phase for Aptensio XR® responders, and a two-week follow-up call after study completion or early discontinuation to assess for ongoing adverse events and concomitant medications. Up to 150 subjects will be enrolled in this trial to allow for subjects who improve significantly during the behavior training phase and drop-outs. Once 74 subjects have completed the double-blind phase, no additional subjects will be enrolled in the trial. Subjects who are already enrolled at that time will be allowed to complete the trial. The primary objective of this study is to establish that an optimal dose of Aptensio XR® will result in a significant reduction in ADHD symptoms compared with placebo in children ages 4 to under 6 years.
Interventions
DRUGAptensio XR
Optimized dose of Aptensio XR (10, 15, 20, 30 or 40 mg) administered orally, once daily
DRUGPlacebo
Placebo capsules
Sponsors
Rhodes Pharmaceuticals, L.P.
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
OTHER
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Masking description
Blinded active capsules looked identical to the same strength placebo capsules
Intervention model description
Randomized, Double-Blind, Placebo-Controlled, Flexible-Dose Titration Study
Eligibility
Sex/Gender
ALL
Age
4 Years to 6 Years
Healthy volunteers
No
Inclusion criteria
1. Male and female subjects ages 48 months to 68 months inclusive at time of consent 2. Met Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM-5) criteria for ADHD, combined, hyperactive/impulsive or inattentive presentation made during a clinical interview by an experienced clinician and confirmed with Kiddie-Sads-Present and Lifetime Version (K-SADS-PL) 3. ADHD symptoms must have been present for at least 6 months 4. Age- and sex-adjusted ratings of ≥ 90th percentile Total Score on the ADHD-RS-IV Preschool Version 5. Score of \< 65 on the Child Global Assessment Scale (CGAS) 6. Must have had a CGI-S score of ≥ 4 at Visit 2 (subjects who were granted a waiver to bypass parental training, and did not have a Visit 2, were still qualified to continue in the study based on their CGI-S score at screening) 7. Estimated intelligence quotient (IQ) ≥ 80 on the Kaufman Brief Intelligence Test, 2nd edition (KBIT-2). If results from the KBIT-2 were deemed invalid because of significant ADHD symptomatology, the PI could submit additional documentation to support average cognitive functioning. This documentation could include progress reports from preschool or other previous testing. These exceptions were evaluated by the Medical Monitor and Study PIs on a case-by-case basis for inclusion. 8. The subject had a parent or legal guardian who would give written informed consent for the subject to participate in the study 9. Subject and parent or legal guardian must have been able to speak and understand English 10. Subject must live with primary caretaker/rater and have been living with primary caretaker for at least 6 months 11. Subject and parent/guardian must have been willing and able to comply with all requirements of the protocol 12. Systolic and diastolic blood pressure below the 95th percentile for age and gender
Exclusion criteria
1. The subject had a lack of response to a trial of adequate dose and duration of MPH or intolerance to previous methylphenidate (MPH) treatment 2. The subject was using any other current psychotropic medication except clonidine, guanfacine, atomoxetine and/or stimulants or had taken an investigational drug in the 30 days prior to screening 3. The subject had used monoamine oxidase inhibitors (MAOIs) within 14 days of the screening visit 4. The subject planned to use prohibited drugs or agents at any point between the screening visit and the end of the study 5. Use of anticonvulsants, antidepressants, or antipsychotics in the 30 days prior to screening 6. The subject should not plan to start any additional psychotherapy outside of the trial during the duration of the study 7. The subject had a history of chronic vocal or motor tics or Tourette's syndrome 8. The subject had any clinically significant ECG abnormalities at screening 9. The subject had any major medical conditions that would have interfered with involvement in the study or could have been affected negatively by methylphenidate 10. The subject had chronic medical illnesses including a seizure disorder (excluding a history of febrile seizures), severe hypertension, untreated thyroid disease, known structural cardiac abnormalities, serious arrhythmias, cardiomyopathy, glaucoma, or a family history of sudden death 11. History (in the past 12 months) or presence of clinically-significant cardiovascular, cerebrovascular, renal, hepatic, gastrointestinal, pulmonary, immunological, hematological, endocrine, or neurological disease that in the opinion of the investigator could have put the subject at risk if he/she participated in the trial or which could have confounded study results 12. Family history (parent or sibling) of structural cardiovascular disease 13. Current or recent (past 12 months) history of drug abuse in someone living in the subject's home 14. Current symptoms or history of major psychiatric illness (for example schizophrenia, psychosis, bipolar disorder, post-traumatic stress disorder, depression, severe anxiety disorder, obsessive compulsive disorder or autistic spectrum disorder) in addition to ADHD that required treatment with additional medication or, in the opinion of the PI, would have contraindicated study participation 15. History or presence of suicidal ideation or significant self-injurious behavior 16. The subject showed evidence of current physical, sexual, or emotional abuse 17. Both biological parents of the subject had a history of bipolar disorder
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Attention Deficit Hyperactivity Disorder Rating Scale - 4th Edition (ADHD-RS-IV) Preschool Version Total Score Change From End of Open Label Phase (Baseline) to End of Double Blind. | 2 weeks: End of open label phase (Baseline) at study day 84 to end of double blind treatment at study day 98. | ADHD-RS-IV is 18-item scale incorporates each of the ADHD symptoms listed in the Diagnostic and Statistical Manual of Mental Disorders, 4th Edition, Text Revision (DSM-IV-TR) regardless of assigned subtype. Scoring was based on the universally accepted symptom severity as recommended in the DSM-IV-TR manual on a 4-point scale: 0 = never or rarely, 1 = sometimes, 2 = often, and 3 = very often. The total score is the sum of the scores for all 18 items and could range from 0 (no impairment) to 54 (maximal impairment) for each administration per subject. Higher score means higher frequency and severity of symptoms. Trained clinicians administered the questionnaire to parents. The ADHD-RS-IV Preschool Version was used to determine eligibility, optimal dosing and the efficacy of double blind treatment. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Attention Deficit Hyperactivity Disorder Rating Scale - 4th Edition (ADHD-RS-IV) Preschool Version Hyperactivity-Impulsivity Subscale Score Change From End of Open Label Phase (Baseline) to End of Double Blind. | 2 weeks: End of open label phase (Baseline) at study day 84 to end of double blind treatment at study day 98. | This 18-item scale incorporates each of the ADHD symptoms listed in the Diagnostic and Statistical Manual of Mental Disorders, 4th Edition, Text Revision (DSM-IV-TR) regardless of assigned subtype. Scoring was based on the universally accepted symptom severity as recommended in the DSM-IV-TR manual on a 4-point scale: 0=never or rarely, 1=sometimes, 2=often, and 3=very often. The Hyperactivity-Impulsivity even items. The Hyperactivity-Impulsivity subscale score was the sum of the scores for the 9 even items and could range from 0 (no impairment) to 27 (maximal impairment) for each administration per subject. Higher score means higher frequency and severity of symptoms. Trained clinicians administered the questionnaire to parents. |
| Attention Deficit Hyperactivity Disorder Rating Scale - 4th Edition (ADHD-RS-IV) Preschool Version Inattention Subscale Score Change From End of Open Label Phase (Baseline) to End of Double Blind. | 2 weeks: End of open label phase (Baseline) at study day 84 to end of double blind treatment at study day 98. | This 18-item scale incorporates each of the ADHD symptoms listed in the Diagnostic and Statistical Manual of Mental Disorders, 4th Edition, Text Revision (DSM-IV-TR) regardless of assigned subtype. Scoring was based on the universally accepted symptom severity as recommended in the DSM-IV-TR manual on a 4-point scale: 0=never or rarely, 1=sometimes, 2=often, and 3=very often. The Inattention subscales were based upon the sum of the odd items. The Inattention subscale score was the sum of the scores for the 9 odd items and could range from 0 (no impairment) to 27 (maximal impairment) for each administration per subject. Higher score means higher frequency and severity of symptoms. Trained clinicians administered the questionnaire to parents. |
| Summary of Clinical Global Impression Scale of Severity (CGI-S) Score From End of Open Label Phase (Baseline) to End of Double Blind. | 2 weeks: End of open label phase (Baseline) at study day 84 to end of double blind treatment at study day 98. | The scale provides a global rating of illness severity during the trial. The subject is rated relative to the clinician's past experience with other subjects who have the same diagnosis. The CGI-S scale is 1 question and rated on a 7-point scale, with the severity of illness scale using a range of responses from 1 (normal) through to 7 (amongst the most severely ill subjects). A lower value a better the outcome. |
| Clinical Global Impression Scale of Improvement (CGI-I) Score at End of Double Blind Phase Relative to End of Open Label Phase (Baseline). | 2 weeks: End of open label phase (Baseline) at study day 84 to end of double blind treatment at study day 98. | The scale provides a global rating of illness improvement during the trial. The subject is rated relative to the clinician's past experience with other subjects who have the same diagnosis. The CGI-I scale is 1 question, and rates improvement compared with a baseline visit using a 7-point scale. The range of responses are from 1 (very much improved) through 7 (very much worse). A lower value is a better the outcome. |
| Conners Early Childhood Behavior - Parent (Short) (EC BEH-P(S)) Change in T-score From End of Open Label Phase (Baseline) to End of Double Blind | 2 weeks: End of open label phase (Baseline) at study day 84 to end of double blind treatment at study day 98. | Conners EC BEH-P(S) is an assessment tool used to obtain a parent's observations about his/her child's behavior. This tool is designed to assess a range of behavioral, emotional, & social issues in young children. The tool consists of 47 items, responses to which are summarized in 6 behavioral scales & 2 validity scales. Items on Conners assessment are rated on a Likert scale ranging from 0-3. The ratings were converted to raw item scores. Raw item scores were grouped, standardized, and/or compared to lookup tables for interpretation. Assessments were presented as T-scores: item raw scores for a given scale are added together; this raw sum is compared to age- and gender-matched normative data and converted to a T-score. Higher scores indicate higher concerns. T-score is a standard score with a mean of 50 and standard deviation of 10. Note that Conners assessments do not use T-scores greater than 90; raw scores that produce extremely high T-scores are reported as ''T-score \>= 90. |
Countries
United States
Participant flow
Recruitment details
The Enrolled Population consisted of all subjects who were not screen failures. Of these enrolled subjects, 119 entered the Open-label Treatment Phase and 90 were randomized to the Double-blind Treatment Phase.
Participants by arm
| Arm | Count |
|---|---|
| Aptensio XR Optimized dose of Aptensio XR administered orally, once daily. | 40 |
| Placebo Comparator Placebo capsules administered orally, once daily. | 50 |
| Total | 90 |
Baseline characteristics
| Characteristic | Aptensio XR | Placebo Comparator | Total |
|---|---|---|---|
| Age, Continuous | 58.5 months STANDARD_DEVIATION 5.59 | 59.2 months STANDARD_DEVIATION 6.42 | 58.9 months STANDARD_DEVIATION 6.05 |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Asian | 0 Participants | 1 Participants | 1 Participants |
| Race (NIH/OMB) Black or African American | 15 Participants | 18 Participants | 33 Participants |
| Race (NIH/OMB) More than one race | 1 Participants | 1 Participants | 2 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) White | 24 Participants | 30 Participants | 54 Participants |
| Sex: Female, Male Female | 29 Participants | 39 Participants | 68 Participants |
| Sex: Female, Male Male | 11 Participants | 11 Participants | 22 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk |
|---|---|---|---|
| deaths Total, all-cause mortality | 0 / 119 | 0 / 40 | 0 / 50 |
| other Total, other adverse events | 82 / 119 | 6 / 40 | 2 / 50 |
| serious Total, serious adverse events | 1 / 119 | 0 / 40 | 0 / 50 |
Outcome results
Primary
Attention Deficit Hyperactivity Disorder Rating Scale - 4th Edition (ADHD-RS-IV) Preschool Version Total Score Change From End of Open Label Phase (Baseline) to End of Double Blind.
ADHD-RS-IV is 18-item scale incorporates each of the ADHD symptoms listed in the Diagnostic and Statistical Manual of Mental Disorders, 4th Edition, Text Revision (DSM-IV-TR) regardless of assigned subtype. Scoring was based on the universally accepted symptom severity as recommended in the DSM-IV-TR manual on a 4-point scale: 0 = never or rarely, 1 = sometimes, 2 = often, and 3 = very often. The total score is the sum of the scores for all 18 items and could range from 0 (no impairment) to 54 (maximal impairment) for each administration per subject. Higher score means higher frequency and severity of symptoms. Trained clinicians administered the questionnaire to parents. The ADHD-RS-IV Preschool Version was used to determine eligibility, optimal dosing and the efficacy of double blind treatment.
Time frame: 2 weeks: End of open label phase (Baseline) at study day 84 to end of double blind treatment at study day 98.
Population: The Efficacy Evaluable (ITT-E) population consists of all subjects in the intent-to-treat (ITT) population who completed ADHD-RS-IV assessments at the end of the open-label treatment phase (i.e., baseline) and had at least one post-baseline ADHD-RS-IV assessment.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Aptensio XR | Attention Deficit Hyperactivity Disorder Rating Scale - 4th Edition (ADHD-RS-IV) Preschool Version Total Score Change From End of Open Label Phase (Baseline) to End of Double Blind. | 6.3 score on a scale | Standard Deviation 12.26 |
| Placebo Comparator | Attention Deficit Hyperactivity Disorder Rating Scale - 4th Edition (ADHD-RS-IV) Preschool Version Total Score Change From End of Open Label Phase (Baseline) to End of Double Blind. | 17.3 score on a scale | Standard Deviation 16.76 |
Secondary
Attention Deficit Hyperactivity Disorder Rating Scale - 4th Edition (ADHD-RS-IV) Preschool Version Hyperactivity-Impulsivity Subscale Score Change From End of Open Label Phase (Baseline) to End of Double Blind.
This 18-item scale incorporates each of the ADHD symptoms listed in the Diagnostic and Statistical Manual of Mental Disorders, 4th Edition, Text Revision (DSM-IV-TR) regardless of assigned subtype. Scoring was based on the universally accepted symptom severity as recommended in the DSM-IV-TR manual on a 4-point scale: 0=never or rarely, 1=sometimes, 2=often, and 3=very often. The Hyperactivity-Impulsivity even items. The Hyperactivity-Impulsivity subscale score was the sum of the scores for the 9 even items and could range from 0 (no impairment) to 27 (maximal impairment) for each administration per subject. Higher score means higher frequency and severity of symptoms. Trained clinicians administered the questionnaire to parents.
Time frame: 2 weeks: End of open label phase (Baseline) at study day 84 to end of double blind treatment at study day 98.
Population: The Efficacy Evaluable (ITT-E) population consists of all subjects in the intent-to-treat (ITT) population who completed ADHD-RS-IV assessments at the end of the open-label treatment phase (i.e., baseline) and had at least one post-baseline ADHD-RS-IV assessment.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Aptensio XR | Attention Deficit Hyperactivity Disorder Rating Scale - 4th Edition (ADHD-RS-IV) Preschool Version Hyperactivity-Impulsivity Subscale Score Change From End of Open Label Phase (Baseline) to End of Double Blind. | 3.36 score on a scale | Standard Deviation 6.434 |
| Placebo Comparator | Attention Deficit Hyperactivity Disorder Rating Scale - 4th Edition (ADHD-RS-IV) Preschool Version Hyperactivity-Impulsivity Subscale Score Change From End of Open Label Phase (Baseline) to End of Double Blind. | 9.37 score on a scale | Standard Deviation 8.762 |
Secondary
Attention Deficit Hyperactivity Disorder Rating Scale - 4th Edition (ADHD-RS-IV) Preschool Version Inattention Subscale Score Change From End of Open Label Phase (Baseline) to End of Double Blind.
This 18-item scale incorporates each of the ADHD symptoms listed in the Diagnostic and Statistical Manual of Mental Disorders, 4th Edition, Text Revision (DSM-IV-TR) regardless of assigned subtype. Scoring was based on the universally accepted symptom severity as recommended in the DSM-IV-TR manual on a 4-point scale: 0=never or rarely, 1=sometimes, 2=often, and 3=very often. The Inattention subscales were based upon the sum of the odd items. The Inattention subscale score was the sum of the scores for the 9 odd items and could range from 0 (no impairment) to 27 (maximal impairment) for each administration per subject. Higher score means higher frequency and severity of symptoms. Trained clinicians administered the questionnaire to parents.
Time frame: 2 weeks: End of open label phase (Baseline) at study day 84 to end of double blind treatment at study day 98.
Population: The Efficacy Evaluable (ITT-E) population consists of all subjects in the intent-to-treat (ITT) population who completed ADHD-RS-IV assessments at the end of the open-label treatment phase (i.e., baseline) and had at least one post-baseline ADHD-RS-IV assessment.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Aptensio XR | Attention Deficit Hyperactivity Disorder Rating Scale - 4th Edition (ADHD-RS-IV) Preschool Version Inattention Subscale Score Change From End of Open Label Phase (Baseline) to End of Double Blind. | 2.9 score on a scale | Standard Deviation 6.48 |
| Placebo Comparator | Attention Deficit Hyperactivity Disorder Rating Scale - 4th Edition (ADHD-RS-IV) Preschool Version Inattention Subscale Score Change From End of Open Label Phase (Baseline) to End of Double Blind. | 7.9 score on a scale | Standard Deviation 8.48 |
Secondary
Clinical Global Impression Scale of Improvement (CGI-I) Score at End of Double Blind Phase Relative to End of Open Label Phase (Baseline).
The scale provides a global rating of illness improvement during the trial. The subject is rated relative to the clinician's past experience with other subjects who have the same diagnosis. The CGI-I scale is 1 question, and rates improvement compared with a baseline visit using a 7-point scale. The range of responses are from 1 (very much improved) through 7 (very much worse). A lower value is a better the outcome.
Time frame: 2 weeks: End of open label phase (Baseline) at study day 84 to end of double blind treatment at study day 98.
Population: The Efficacy Evaluable (ITT-E) population consists of all subjects in the intent-to-treat (ITT) population who completed ADHD-RS-IV assessments at the end of the open-label treatment phase (i.e., baseline) and had at least one post-baseline ADHD-RS-IV assessment.
| Arm | Measure | Category | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Aptensio XR | Clinical Global Impression Scale of Improvement (CGI-I) Score at End of Double Blind Phase Relative to End of Open Label Phase (Baseline). | 4 = No change | 11 Participants |
| Aptensio XR | Clinical Global Impression Scale of Improvement (CGI-I) Score at End of Double Blind Phase Relative to End of Open Label Phase (Baseline). | 1 = Very much improved | 6 Participants |
| Aptensio XR | Clinical Global Impression Scale of Improvement (CGI-I) Score at End of Double Blind Phase Relative to End of Open Label Phase (Baseline). | 3 = Minimally improved | 3 Participants |
| Aptensio XR | Clinical Global Impression Scale of Improvement (CGI-I) Score at End of Double Blind Phase Relative to End of Open Label Phase (Baseline). | 2 = Much improved | 8 Participants |
| Aptensio XR | Clinical Global Impression Scale of Improvement (CGI-I) Score at End of Double Blind Phase Relative to End of Open Label Phase (Baseline). | 5 = Minimally worse | 4 Participants |
| Aptensio XR | Clinical Global Impression Scale of Improvement (CGI-I) Score at End of Double Blind Phase Relative to End of Open Label Phase (Baseline). | 6 = Much worse | 6 Participants |
| Aptensio XR | Clinical Global Impression Scale of Improvement (CGI-I) Score at End of Double Blind Phase Relative to End of Open Label Phase (Baseline). | 7 = Very much worse | 1 Participants |
| Placebo Comparator | Clinical Global Impression Scale of Improvement (CGI-I) Score at End of Double Blind Phase Relative to End of Open Label Phase (Baseline). | 6 = Much worse | 16 Participants |
| Placebo Comparator | Clinical Global Impression Scale of Improvement (CGI-I) Score at End of Double Blind Phase Relative to End of Open Label Phase (Baseline). | 3 = Minimally improved | 4 Participants |
| Placebo Comparator | Clinical Global Impression Scale of Improvement (CGI-I) Score at End of Double Blind Phase Relative to End of Open Label Phase (Baseline). | 4 = No change | 13 Participants |
| Placebo Comparator | Clinical Global Impression Scale of Improvement (CGI-I) Score at End of Double Blind Phase Relative to End of Open Label Phase (Baseline). | 7 = Very much worse | 5 Participants |
| Placebo Comparator | Clinical Global Impression Scale of Improvement (CGI-I) Score at End of Double Blind Phase Relative to End of Open Label Phase (Baseline). | 1 = Very much improved | 5 Participants |
| Placebo Comparator | Clinical Global Impression Scale of Improvement (CGI-I) Score at End of Double Blind Phase Relative to End of Open Label Phase (Baseline). | 5 = Minimally worse | 1 Participants |
| Placebo Comparator | Clinical Global Impression Scale of Improvement (CGI-I) Score at End of Double Blind Phase Relative to End of Open Label Phase (Baseline). | 2 = Much improved | 6 Participants |
Secondary
Conners Early Childhood Behavior - Parent (Short) (EC BEH-P(S)) Change in T-score From End of Open Label Phase (Baseline) to End of Double Blind
Conners EC BEH-P(S) is an assessment tool used to obtain a parent's observations about his/her child's behavior. This tool is designed to assess a range of behavioral, emotional, & social issues in young children. The tool consists of 47 items, responses to which are summarized in 6 behavioral scales & 2 validity scales. Items on Conners assessment are rated on a Likert scale ranging from 0-3. The ratings were converted to raw item scores. Raw item scores were grouped, standardized, and/or compared to lookup tables for interpretation. Assessments were presented as T-scores: item raw scores for a given scale are added together; this raw sum is compared to age- and gender-matched normative data and converted to a T-score. Higher scores indicate higher concerns. T-score is a standard score with a mean of 50 and standard deviation of 10. Note that Conners assessments do not use T-scores greater than 90; raw scores that produce extremely high T-scores are reported as ''T-score \>= 90.
Time frame: 2 weeks: End of open label phase (Baseline) at study day 84 to end of double blind treatment at study day 98.
Population: The Efficacy Evaluable (ITT-E) population consists of all subjects in the intent-to-treat (ITT) population who completed ADHD-RS-IV assessments at the end of the open-label treatment phase (i.e., baseline) and had at least one post-baseline ADHD-RS-IV assessment.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Aptensio XR | Conners Early Childhood Behavior - Parent (Short) (EC BEH-P(S)) Change in T-score From End of Open Label Phase (Baseline) to End of Double Blind | Inattention/Hyperactivity | 1.92 T-score | Standard Deviation 11.412 |
| Aptensio XR | Conners Early Childhood Behavior - Parent (Short) (EC BEH-P(S)) Change in T-score From End of Open Label Phase (Baseline) to End of Double Blind | Defiant/Aggressive Behaviors | 1.00 T-score | Standard Deviation 11.016 |
| Aptensio XR | Conners Early Childhood Behavior - Parent (Short) (EC BEH-P(S)) Change in T-score From End of Open Label Phase (Baseline) to End of Double Blind | Mood and Affect | 2.63 T-score | Standard Deviation 11.78 |
| Aptensio XR | Conners Early Childhood Behavior - Parent (Short) (EC BEH-P(S)) Change in T-score From End of Open Label Phase (Baseline) to End of Double Blind | Social Functioning / Atypical Behaviors | 3.79 T-score | Standard Deviation 10.437 |
| Aptensio XR | Conners Early Childhood Behavior - Parent (Short) (EC BEH-P(S)) Change in T-score From End of Open Label Phase (Baseline) to End of Double Blind | Anxiety | 1.89 T-score | Standard Deviation 10.211 |
| Aptensio XR | Conners Early Childhood Behavior - Parent (Short) (EC BEH-P(S)) Change in T-score From End of Open Label Phase (Baseline) to End of Double Blind | Physical Symptoms | 1.92 T-score | Standard Deviation 13.2 |
| Placebo Comparator | Conners Early Childhood Behavior - Parent (Short) (EC BEH-P(S)) Change in T-score From End of Open Label Phase (Baseline) to End of Double Blind | Mood and Affect | 5.13 T-score | Standard Deviation 12.335 |
| Placebo Comparator | Conners Early Childhood Behavior - Parent (Short) (EC BEH-P(S)) Change in T-score From End of Open Label Phase (Baseline) to End of Double Blind | Inattention/Hyperactivity | 7.73 T-score | Standard Deviation 15.067 |
| Placebo Comparator | Conners Early Childhood Behavior - Parent (Short) (EC BEH-P(S)) Change in T-score From End of Open Label Phase (Baseline) to End of Double Blind | Social Functioning / Atypical Behaviors | 3.83 T-score | Standard Deviation 11.96 |
| Placebo Comparator | Conners Early Childhood Behavior - Parent (Short) (EC BEH-P(S)) Change in T-score From End of Open Label Phase (Baseline) to End of Double Blind | Defiant/Aggressive Behaviors | 3.67 T-score | Standard Deviation 11.033 |
| Placebo Comparator | Conners Early Childhood Behavior - Parent (Short) (EC BEH-P(S)) Change in T-score From End of Open Label Phase (Baseline) to End of Double Blind | Anxiety | -0.02 T-score | Standard Deviation 8.299 |
| Placebo Comparator | Conners Early Childhood Behavior - Parent (Short) (EC BEH-P(S)) Change in T-score From End of Open Label Phase (Baseline) to End of Double Blind | Physical Symptoms | -0.15 T-score | Standard Deviation 11.13 |
Secondary
Summary of Clinical Global Impression Scale of Severity (CGI-S) Score From End of Open Label Phase (Baseline) to End of Double Blind.
The scale provides a global rating of illness severity during the trial. The subject is rated relative to the clinician's past experience with other subjects who have the same diagnosis. The CGI-S scale is 1 question and rated on a 7-point scale, with the severity of illness scale using a range of responses from 1 (normal) through to 7 (amongst the most severely ill subjects). A lower value a better the outcome.
Time frame: 2 weeks: End of open label phase (Baseline) at study day 84 to end of double blind treatment at study day 98.
Population: The Efficacy Evaluable (ITT-E) population consists of all subjects in the intent-to-treat (ITT) population who completed ADHD-RS-IV assessments at the end of the open-label treatment phase (i.e., baseline) and had at least one post-baseline ADHD-RS-IV assessment.
| Arm | Measure | Group | Category | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|---|
| Aptensio XR | Summary of Clinical Global Impression Scale of Severity (CGI-S) Score From End of Open Label Phase (Baseline) to End of Double Blind. | End of Double-blind Treatment | 7 = Among the most extremely ill subjects | 0 Participants |
| Aptensio XR | Summary of Clinical Global Impression Scale of Severity (CGI-S) Score From End of Open Label Phase (Baseline) to End of Double Blind. | Baseline | 1 = Normal, not at all ill | 7 Participants |
| Aptensio XR | Summary of Clinical Global Impression Scale of Severity (CGI-S) Score From End of Open Label Phase (Baseline) to End of Double Blind. | Baseline | 2 = Borderline mentally ill | 15 Participants |
| Aptensio XR | Summary of Clinical Global Impression Scale of Severity (CGI-S) Score From End of Open Label Phase (Baseline) to End of Double Blind. | Baseline | 3 = Mildly ill | 8 Participants |
| Aptensio XR | Summary of Clinical Global Impression Scale of Severity (CGI-S) Score From End of Open Label Phase (Baseline) to End of Double Blind. | Baseline | 4 = Moderately ill | 7 Participants |
| Aptensio XR | Summary of Clinical Global Impression Scale of Severity (CGI-S) Score From End of Open Label Phase (Baseline) to End of Double Blind. | Baseline | 5 = Markedly ill | 1 Participants |
| Aptensio XR | Summary of Clinical Global Impression Scale of Severity (CGI-S) Score From End of Open Label Phase (Baseline) to End of Double Blind. | Baseline | 6 = Severely ill | 1 Participants |
| Aptensio XR | Summary of Clinical Global Impression Scale of Severity (CGI-S) Score From End of Open Label Phase (Baseline) to End of Double Blind. | Baseline | 7 = Among the most extremely ill subjects | 0 Participants |
| Aptensio XR | Summary of Clinical Global Impression Scale of Severity (CGI-S) Score From End of Open Label Phase (Baseline) to End of Double Blind. | End of Double-blind Treatment | 1 = Normal, not at all ill | 4 Participants |
| Aptensio XR | Summary of Clinical Global Impression Scale of Severity (CGI-S) Score From End of Open Label Phase (Baseline) to End of Double Blind. | End of Double-blind Treatment | 2 = Borderline mentally ill | 12 Participants |
| Aptensio XR | Summary of Clinical Global Impression Scale of Severity (CGI-S) Score From End of Open Label Phase (Baseline) to End of Double Blind. | End of Double-blind Treatment | 3 = Mildly ill | 5 Participants |
| Aptensio XR | Summary of Clinical Global Impression Scale of Severity (CGI-S) Score From End of Open Label Phase (Baseline) to End of Double Blind. | End of Double-blind Treatment | 4 = Moderately ill | 6 Participants |
| Aptensio XR | Summary of Clinical Global Impression Scale of Severity (CGI-S) Score From End of Open Label Phase (Baseline) to End of Double Blind. | End of Double-blind Treatment | 5 = Markedly ill | 10 Participants |
| Aptensio XR | Summary of Clinical Global Impression Scale of Severity (CGI-S) Score From End of Open Label Phase (Baseline) to End of Double Blind. | End of Double-blind Treatment | 6 = Severely ill | 2 Participants |
| Placebo Comparator | Summary of Clinical Global Impression Scale of Severity (CGI-S) Score From End of Open Label Phase (Baseline) to End of Double Blind. | Baseline | 7 = Among the most extremely ill subjects | 0 Participants |
| Placebo Comparator | Summary of Clinical Global Impression Scale of Severity (CGI-S) Score From End of Open Label Phase (Baseline) to End of Double Blind. | End of Double-blind Treatment | 7 = Among the most extremely ill subjects | 2 Participants |
| Placebo Comparator | Summary of Clinical Global Impression Scale of Severity (CGI-S) Score From End of Open Label Phase (Baseline) to End of Double Blind. | End of Double-blind Treatment | 4 = Moderately ill | 10 Participants |
| Placebo Comparator | Summary of Clinical Global Impression Scale of Severity (CGI-S) Score From End of Open Label Phase (Baseline) to End of Double Blind. | Baseline | 1 = Normal, not at all ill | 13 Participants |
| Placebo Comparator | Summary of Clinical Global Impression Scale of Severity (CGI-S) Score From End of Open Label Phase (Baseline) to End of Double Blind. | End of Double-blind Treatment | 1 = Normal, not at all ill | 3 Participants |
| Placebo Comparator | Summary of Clinical Global Impression Scale of Severity (CGI-S) Score From End of Open Label Phase (Baseline) to End of Double Blind. | Baseline | 2 = Borderline mentally ill | 14 Participants |
| Placebo Comparator | Summary of Clinical Global Impression Scale of Severity (CGI-S) Score From End of Open Label Phase (Baseline) to End of Double Blind. | End of Double-blind Treatment | 6 = Severely ill | 7 Participants |
| Placebo Comparator | Summary of Clinical Global Impression Scale of Severity (CGI-S) Score From End of Open Label Phase (Baseline) to End of Double Blind. | Baseline | 3 = Mildly ill | 11 Participants |
| Placebo Comparator | Summary of Clinical Global Impression Scale of Severity (CGI-S) Score From End of Open Label Phase (Baseline) to End of Double Blind. | End of Double-blind Treatment | 2 = Borderline mentally ill | 5 Participants |
| Placebo Comparator | Summary of Clinical Global Impression Scale of Severity (CGI-S) Score From End of Open Label Phase (Baseline) to End of Double Blind. | Baseline | 4 = Moderately ill | 11 Participants |
| Placebo Comparator | Summary of Clinical Global Impression Scale of Severity (CGI-S) Score From End of Open Label Phase (Baseline) to End of Double Blind. | End of Double-blind Treatment | 5 = Markedly ill | 19 Participants |
| Placebo Comparator | Summary of Clinical Global Impression Scale of Severity (CGI-S) Score From End of Open Label Phase (Baseline) to End of Double Blind. | Baseline | 5 = Markedly ill | 1 Participants |
| Placebo Comparator | Summary of Clinical Global Impression Scale of Severity (CGI-S) Score From End of Open Label Phase (Baseline) to End of Double Blind. | End of Double-blind Treatment | 3 = Mildly ill | 4 Participants |
| Placebo Comparator | Summary of Clinical Global Impression Scale of Severity (CGI-S) Score From End of Open Label Phase (Baseline) to End of Double Blind. | Baseline | 6 = Severely ill | 0 Participants |